Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-68P is a nonfunctional pseudogene derived from U6 snRNA, an essential component of the spliceosome complex involved in the excision of introns from pre-mRNA[3][4]. Pseudogenes such as RNU6-68P are created by retrotransposition events, frequently involving LINE-1 elements, which copy and insert RNA gene sequences back into the genome[1][5]. While functional U6 snRNA is highly conserved and crucial for mRNA splicing, pseudogenes like RNU6-68P do not produce active RNA or have known biological activity[4][5]. Instead, they serve as markers of genome evolution and retrotransposon activity. RNU6-68P is not considered a drug target, does not encode a receptor, enzyme, or functional protein, and has no validated clinical or pharmacological relevance. RNU6-68P is not a receptor, enzyme, or any conventional “target” relevant for drug development or therapeutic intervention; it is a retrotransposed pseudogene, not an active molecular species[4][5]. It is not misspelled, but may be incorrectly listed as a target in databases focused on functional biomolecules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 68, pseudogene (RNU6-68P).